

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Pectin-honey hydrogel: Characterization, antimicrobial activity and biocompatibility

This is the author's manuscript

Original Citation:

Pectin-honey hydrogel: Characterization, antimicrobial activity and biocompatibility / Giusto, Gessica; Beretta, Giangiacomo; Vercelli, Cristina; Valle, Emanuela; Iussich, Selina; Borghi, Roberta; Odetti, Patrizio; Monacelli, Fiammetta; Tramuta, Clara; Grego, Elena; Nebbia, Patrizia; Robino, Patrizia; Odore, Rosangela; Gandini, Marco. - In: BIO-MEDICAL MATERIALS AND ENGINEERING. - ISSN 0959-2989. - 29:3(2018), pp. 347-356.

Availability:

This version is available <http://hdl.handle.net/2318/1665570> since 2018-04-12T11:03:19Z

Published version:

DOI:10.3233/BME-181730

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **Pectin-honey hydrogel: characterization, antimicrobial activity and biocompatibility**

2

3 Gessica Giusto^a, Giangiacomo Beretta^b, Cristina Vercelli^a, Emanuela Valle^a, Selina Iussich^a,
4 Roberta Borghi^c, Patrizio Odetti^c, Fiammetta Monacelli^c, Clara Tramuta^a, Elena Grego^a, Patrizia
5 Nebbia^a, Patrizia Robino^a, Rosangela Odore^a, Marco Gandini^a

6

7 ^a Department of Veterinary Sciences, University of Turin, Largo Paolo Braccini 2-5, 10095
8 Grugliasco (TO), Italy

9 ^b Department of Pharmaceutical Sciences DISFARM, University of Milan, Via Mangiagalli 25,
10 20133 Milano (MI), Italy

11 ^c Department of Internal Medicine and Medical Specialties, University of Genoa, Viale Benedetto
12 XV 6, 16132 Genova (GE), Italy

13

14

15 Address correspondence to Dr. Gandini at marco.gandini@unito.it from the Department of
16 Veterinary Sciences, University of Turin, Largo Paolo Braccini 2-5, 10095 Grugliasco (TO),
17 Italy, phone +390116708861

18

19

20

21

22

23

24

25 **Abstract**

26 **Background:** Novel pectin-honey hydrogels have been developed and characterized as medical
27 device. Ideally, a wound dressing should maintain optimal fluid affinity, permit moisture
28 evaporation, protect the wound from microbes, and have shape-conformability, biocompatibility,
29 and antibacterial activity. **Objective:** A novel, simple and fast method to produce pectin-honey
30 wound dressings is described. **Methods:** The properties of these pectin-honey hydrogels were
31 investigated, including swelling ability, water vapour transmission rate, hydrogen peroxide
32 production, methylglyoxal content and antibacterial activity. Biocompatibility was assessed by
33 proliferation assays using cultured fibroblast cells and by *in vivo* study with subcutaneous and
34 intraperitoneal implantation in rats. **Results:** Hydrogel showed a good water vapour transmission
35 rate, fluid uptake and were not cytotoxic for fibroblasts. The hydrogel demonstrated good
36 antibacterial activity toward clinically relevant pathogens, including *S. aureus* and *E. coli*.
37 Biocompatibility was confirmed by the measurement of plasma levels of interleukin (IL)1 beta,
38 IL-6, tumour necrosis factor (TNF) alpha, and prostaglandin (PG)E2. No histological changes
39 were observed. **Conclusions:** The presence of a natural active component, conformability, and
40 complete resorbability are the main characteristics of this new biocompatible biomaterial that is
41 well tolerated by the body, possibly improves healing, may be used for surgical complications
42 prevention, with a simple and inexpensive production process.

43

44 **Keywords:** biocompatibility, biomaterial, pectin-honey hydrogels, wound dressing, medical
45 device

46

47

48

49 **Introduction**

50 Healing wounds are sites that are easily attacked by bacteria, which leads to the formation of a
51 biofilm that devitalises tissues [1]. The development of a new wound dressing is a focus area for
52 many researchers since the dressing can create a barrier against infection while maintaining a
53 physiological environment in contact with the wound [2-3]. These dressings help to maintain a
54 moist environment at the wound site, promote tissue healing, and reduce infection, pain, and
55 costs [1, 4-5]. Antimicrobial agents play an important role in reducing bacterial contamination,
56 but the resistance of pathogens to these substances has led to a decrease in the efficacy of
57 antibiotics. Researchers have therefore advised against the use of systemic antimicrobial agents
58 for the treatment of wounds [1, 6].

59 Various wound dressings consisting of vegetable fibres, protective films, hydrogels, and hydrogel
60 enriched with nitrogen oxides are available commercially [1-2, 5, 7]. Hydrogels are reported to be
61 suitable for use in healing wounds but they have limitations in current use, which include a
62 requirement for high frequency of application, inactivation by wound fluids, and formation of
63 eschars [5]. The requirement for a new antimicrobial substance led to reevaluation of ancient
64 remedies, including the use of honey [8-9].

65 Honey has been used alone or in combination with other compounds for medical use since
66 ancient times. Honey is a heterogeneous substance, has antimicrobial activity, anti-inflammatory
67 effects and increase the healing process following skin or peritoneal damage [8, 10]. It contains
68 high levels of glycine, methionine and proline which are all fundamental for collagen formation
69 and fibroblast deposition, which are the main factors for wound healing [11].

70 Manuka honey, produced in New Zealand, is the most studied honey having antibacterial
71 properties against major aerobic and anaerobic bacteria species [12-13].

72 Several components are known to contribute antibacterial activity of honey. The osmotic effect of
73 the sugars in honey and its characteristically acidic pH are known factors hindering bacterial
74 multiplication. Recently, two components of honey, hydrogen peroxide (H₂O₂) and
75 methylglyoxal (MGO), have been identified as effective antibacterials [14-16].

76 An ideal wound dressing is yet to be developed. Ideally, a wound dressing should maintain
77 optimal fluid affinity, permit moisture evaporation, protect the wound from foreign microbes, and
78 have shape-conformability, biocompatibility, and antibacterial activity [2,4-5,17].

79 Based on these premises, the aim of the present study was to describe and characterize the
80 properties of pectin-honey hydrogels (PHHs) for wound healing and to assess their
81 biocompatibility through an in vitro and in vivo assay.

82 **Material and methods**

83 *Materials*

84 Honey was purchased from Manuka Health (66 Weona Court, Te Awamutu 3800, New Zealand)
85 and pectin from Ardet s.r.l. (Torino, Italy). Culture media, that is, tryptone soy agar (TSA),
86 tryptone soy broth (TSB), peptone water, and 5% sheep blood agar, were purchased from Oxoid
87 (Milan, Italy). Escherichia coli (Turin strain) and Staphylococcus aureus (Turin strain) isolated
88 from canine wounds were used for this work.

89 *Preparation of PHHs*

90 The preparation method was modified after the procedure described by Walker. (Walker, 1942)
91 [18] Briefly, the pectin-honey hydrogels were prepared starting from a solution (1:1 v/v) of liquid
92 honey (Manuka Health, New Zealand) and sterile deionized water. The same volume of pectin
93 powder (ARDET s.r.l., Italy) was then added and with continuous stirring until the mixture was
94 homogeneous. The resulting gel was spread into 2 mm thick films and hot air dried at 40± 0.5
95 °C for 6 h. Then it was cut into squares of 5 x 5 cm and further conditioned in an air drier at 25±

96 1 °C for 5 days. The films were then collected and packed in polyethylene under vacuum
97 conditions. All membranes were sterilized by gamma-irradiation at 25 KGray at the Sterigenics
98 Italy (Sterigenics Italy, Minerbio (BO), Italy) [19].

99 ***Fluid uptake test (Swelling test)***

100 To investigate the fluid swelling ratio of PHHs, samples were cut into disks with a diameter of
101 approximately 25 mm. The dry weights (W_{dry}) of the membranes were measured and recorded.
102 Afterwards, pre-weighed dry samples were immersed in PBS solution, pH 7.4, at 37°C. The
103 weights of the swollen PHHs were determined every 5 min subsequently by sandwiching the
104 membranes between two paper towels to remove excess water on the surface, and then wet
105 weights (W_{wet}) were measured. All experiments were performed in triplicate. The swelling
106 ratios were calculated as the average value according to the following formula:

$$107 \quad DS = [(W_w - W_d)/W_d] \times 100$$

108 Where W_w and W_d represent the weights of wet and dry samples, respectively.

109 ***Water vapour transmission rate (WVTR)***

110 The moisture permeability of the PHH was determined by measuring the WVTR. A piece of the
111 specimen was fixed over the top of a tube (diameter, 34 mm) containing 10 mL PBS. The tube
112 was then placed in an incubator at 37°C and 35% relative humidity. The membranes were
113 weighed at regular intervals of time and the weight loss was recorded and plotted on a graph
114 versus time. The WVTR was calculated from the slope of the graph by the following formula:

$$115 \quad WVTR \text{ g (m}^2\text{/day)} = (\text{slope} \times 24)/A$$

116 Where A is area of the sample (m^2). Experiments were performed in triplicate.

117 ***H₂O₂ analysis***

118 The analysis of H_2O_2 from honey and PHHs was carried out according to the method reported by
119 Long (1999) [20] (ferrous ion oxidation-xylenol orange [FOX] assay), with minor modifications.

120 The stock reagents were as follows: reagent 1, 4.4 mM butylated hydroxy toluene (BHT) in
121 HPLC-grade methanol; reagent 2, 1 mM xylenol orange and 2.56 mM ammonium ferrous
122 sulphate in 250 mM H₂SO₄; working reagent: one volume of reagent 2 added to nine volumes of
123 reagent 1. Approximately 200 mg of honey were diluted with deionized water to the ratio 20%
124 w/w and immediately kept in a thermostat at T = 37 °C, and 100-μL aliquots were added to 900
125 μl of FOX working reagent. After 20 min of incubation at room temperature, absorbance was
126 measured at λ= 560 nm against a blank comprising 900 μL of working reagent and 100- μL
127 aliquots of distilled water (absorbance of diluted honey was negligible at the operative
128 wavelength). H₂O₂ was monitored at 5, 10, 15, 20, 30, 60, and 120 min and up to 24 and 48 h of
129 incubation.

130 To reduce the processing time required to extract the water-soluble components from PHHs, their
131 size was reduced prior to incubation by cutting the specimens into small pieces with the aid of a
132 small and clean knife. Aliquots of 100 μL of the aqueous layer of the final mixture (40% w/w)
133 were subjected to FOX analysis as described above for honey. Monitoring of H₂O₂ was carried
134 out at 60 min, 90 min, 24 h, and 48 h. The FOX assay was calibrated using standard H₂O₂
135 (molar extinction coefficient, 43 M⁻¹ cm⁻¹; absorbance wave length of H₂O₂ λ = 240 nm; linear
136 range, 0–50 μM). Ten units of catalase were sufficient to destroy all the H₂O₂ immediately.
137 Controls with catalase were used to exclude interference due to honey constituents.

138 *Methylglyoxal (MGO) analysis*

139 MGO was evaluated by the method proposed by Wild (2012) [21] with slight modifications. The
140 method is based on the reaction between N-acetyl-L-cysteine (Sigma Aldrich) and MGO at room
141 temperature. Samples were diluted in water (340 mg/ml) and the reaction was performed in 100
142 mM sodium dihydrogen phosphate buffer (adjusted to pH 7.0 with 10 M NaOH) at 22 °C. For the
143 standard curve of the reaction, different concentrations of MGO (0.5, 1, 2, and 5 mM) were used.

144 MGO solutions (Sigma Aldrich) equivalent to 0.5, 2, and 5 mM and 10 μ L of each honey solution
145 (170 mg HBM/ml water) were added up to a volume of 980 μ L with sodium dihydrogen
146 phosphate. The reaction was started by adding 20 μ L 500 mM N-acetyl-L-cysteine, and the
147 absorption was recorded after 7 min. The condensation product, N- α -acetyl-S-(1-hydroxy-2-oxo-
148 prop-1-yl) cysteine, was determined by recording the absorption at 288 nm (UVIKON 923, Bio-
149 Tek Instrument). Results are given in μ mol/mg of honey.

150 ***Protein content analysis of honeys***

151 Honey samples were diluted in water and the protein content was determined using the BCA
152 protein assay kit according to the manufacturer's instructions (Pierce, BCA Protein Assay).

153 ***Microbiological analysis***

154 The success of sterilization was verified by the absence of bacterial growth on solid medium (5%
155 sheep blood agar) at 37 °C for 24 h, both in aerobiosis and anaerobiosis. Subsequently, the
156 antibacterial activity of PHHs was determined against *S. aureus* and *E. coli*, which had been
157 previously isolated from canine wound infections. The agar good diffusion method was used to
158 screen the antimicrobial activity of the Manuka PHHs [22]. Clinical strains were grown overnight
159 in TSB at 37°C and adjusted to 0.5 McFarland standard. Each culture was inoculated on the
160 surface of Petri plates. Subsequently, wells with 6-mm diameter were bored into the surface of
161 the agar. The wells were filled with 6 mm of a Manuka honey-based patch, 80 μ L of a Manuka
162 honey sample 100% v/v (as positive control), 80 μ L of a Manuka honey sample 50% v/v (as a
163 positive control that resembles the concentration of honey present in PHHs), and 6 mm of pectin
164 (as negative control). Plates were incubated at 37°C, and after 24 h, the diameters of the
165 inhibition zones were measured. Each assay was carried out in triplicate.

166 ***In vitro cytotoxicity assay***

167 The cytocompatibility of PHHs was evaluated using L929 cells (mice fibroblasts) (ECACC Cell
168 Lines-Sigma Aldrich, Milan, Italy) that were cultured in 75 mL flasks containing Modified
169 Eagles Medium (MEM; Sigma Aldrich, Milan, Italy), 10% fetal bovine serum (FBS; Sigma
170 Aldrich, Milan, Italy), 2% L-glutamine (Sigma Aldrich, Milan, Italy), and 2% penicillin-
171 streptomycin-amphotericin B solution (Sigma Aldrich) at 37°C with 5% CO₂, 95% air, and
172 complete humidity. When a confluence of 80% was reached, cells were detached using 0.1%
173 trypsin/EDTA solution (Sigma Aldrich, Milan, Italy), centrifuged, and counted using Trypan
174 Blue solution (Sigma Aldrich) with a Burker chamber. Cells were either resuspended at a
175 concentration of 5×10⁵ cells/mL or stored at -80°C for further analysis. The 3-(4,5-
176 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay, a routine method
177 for quantifying cell viability, was used [23].

178 Cells (5×10⁵ cells/100 μL) were transferred into 96-well plates in order to perform the MTT
179 assay at 24, 48, and 72 hours after seeding. After an overnight incubation at 37°C and 5% CO₂,
180 the medium was changed (MEM, FBS 10%, antibiotic and antimycotic solution 2%, L-glutamine
181 2%), and serial decreasing concentrations of honey membranes dissolved in phosphate buffered
182 saline (PBS) solution, starting from 0.1 g/ml, were added. After adding MTT (Sigma Aldrich,
183 Milan, Italy) solution (4 mg/ml in PBS), the plates were incubated at 37 °C and 5% CO₂ for 4
184 hours. At the end of incubation, the medium was removed, and 100 μL of dimethyl sulfoxide
185 (DMSO; Sigma Aldrich, Milan, Italy) was added in order to lysate the formazan crystals. The
186 plates were further incubated for 10 minutes on a continuous shaker at room temperature, and the
187 optical density of the wells was determined using a plate reader (Poverwave x; Bio-Tek
188 Instruments Inc., Winooski, USA) at a wavelength of 570 nm.

189 ***In vivo biocompatibility study***

190 All procedures were approved by the Bioethical Committee of the University of Turin and by the
191 Italian Ministry of Health (protocol number 304/2015-PR, 20/04/2015).

192 A total of 39 adult male Sprague-Dawley rats, weighing 225-250 grams, were purchased by
193 Harlan Laboratories (Italy). All rats were housed in single cages for 7 days prior to the beginning
194 of the experiment. The room temperature was set at 23°C throughout the duration of the
195 experiment and cages were cleaned daily. Animals were fed with a commercial diet and water
196 was given ad libitum. Anaesthesia was induced by administering 5 mg/kg of xylazine
197 (Rompum®, Bayer Animal Health, Italy) and 50 mg/kg of tiletamine and zolazepam (Zoletil 50,
198 Virbac, Italy) intramuscularly. Anaesthesia lasted for approximately 1 hour. Under anaesthesia,
199 blood samples were collected from the caudal vein to perform biochemical analysis. Soon after,
200 the ventral hair was shaved and the skin was prepared using a 3-step iodopovidone –
201 chlorhexidine scrub. The animals were randomly assigned to the treatment or control groups. A
202 4-cm midline incision was made in the abdominal wall. In the treatment group, subcutaneous and
203 intraperitoneal implantation of PHH was performed as previously described [24]. Briefly, one
204 square each of PHH measuring 1 × 1 cm was implanted intraperitoneally under the left
205 abdominal wall and subcutaneously at ~1 cm left to the midline between the muscle and skin. In
206 the control group, only the surgical procedure was performed without PHH implantation. In both
207 groups, the midline incision was closed in two layers, with 3-0 USP glycomer 631 for the fascia,
208 and with 3-0 USP nylon for the skin. Each surgical procedure lasted about ~20 minutes.

209 Blood samples for the biochemical analysis were collected from the caudal vein. The blood was
210 collected into tubes before surgery and at 6 h (T6), 24 h (T24), and 72 h (T72) post-surgery and at
211 the time of euthanasia. Plasma levels of IL-1 β , IL-6, TNF- α and PG(E2) were measured by using
212 a commercial ELISA kit (Rat IL1 beta ELISA kit, Booster Biological Technology; Rat Il-6

213 ELISA, AB Frontier; Rat TNF alpha ELISA, AB Frontier; Prostaglandin E2 Express EIA kit,
214 Cayman Chemical).

215 At 0, 6, 24, 72 hour's post-surgery, three rats from each group were euthanized and target organs
216 (liver, kidney, left abdominal wall) were collected and fixed in 4% formaldehyde. These tissues
217 were sectioned, stained in H&E, and observed by two pathologists in a blinded manner [24].

218 ***Statistical analysis***

219 Normality of the data was evaluated using the Shapiro–Wilk normality test. For the in vitro
220 cytotoxicity assay, all experiments were performed in triplicate, and the data are representative of
221 at least three independent experiments. The results, expressed as mean \pm SEM values, were
222 analysed using the Kruskal-Wallis test and a Dunn's post-test.

223 For plasma cytokine levels, all experiments were performed in duplicate. For IL-1 β , IL-6, and
224 TNF- α , the results have been expressed as median (95% IC) values and were analysed using the
225 one-way ANOVA test. For PG(E2), the results are expressed as median (95% IC) and were
226 analysed using the Friedman test. Statistical analysis was performed with the GraphPad Prism
227 6.01 software. Values with $p < 0.05$ were considered significant.

228 **Results**

229 ***Fluid uptake test (swelling test)***

230 The weight of PHHs immersed in PBS solution under physiological mimicking conditions (pH
231 7.4, 37°C). The fluid content increased to about 150% after 180 minutes. The results from the
232 fluid uptake experiment revealed that the dressing has wide capacity to prevent fluid
233 accumulation if used on wound.

234 ***WVTR***

235 The transmission of water vapour through the membranes is an important parameter for the
236 evaluation of their effectiveness as a hydration factor when placed on a wound. The WVTR

237 recommended for wound dressing is 2000–2500 g/m²/day in order to ensure proper wound
238 moisture without risk of dehydration or excessive production of exudates [1,4]. A good WVTR
239 facilitates the healing process because it improves cell migration and promotes re-
240 epithelialization.

241 The water loss from a fully hydrated dressing on exposure to air was evaluated. The mean
242 evaporative water loss from PHHs was 2689.8 ± 158.5 g/m²/day.

243 ***H₂O₂-producing activity***

244 All the honey samples, before inclusion in the membranes, were able to produce significant
245 amounts of H₂O₂ while no H₂O₂ development was observed in the case of corresponding PHHs
246 (data not shown). In Manuka honey, at shorter incubation times up to 90 min of incubation, the
247 concentration of H₂O₂ generated by honey glucose oxidase was in the range reported in the
248 literature for other types of honey with different methods of analyses (1–2 mM at 30 min of
249 incubation) [16, 25-27]. By contrast, Manuka honey showed the lowest H₂O₂ production at all
250 incubation times, probably because of its high content of MGO, which has previously been
251 suggested to be a glucose oxidase-inhibitory agent [16, 25]. At longer incubation times (24 and
252 48 h), the tested honey samples displayed a significantly different behaviour: The dramatic loss
253 of H₂O₂ producing activity found for PHHs indicated that their production procedure, which
254 included a heating step at 80 °C and exposure to γ -rays for final sterilization, induced complete
255 loss of glucose oxidase activity. This demonstrated that the preserved antibacterial activity in the
256 microbiological testing was generated solely by the action of nonperoxide agents.

257 ***MGO analysis***

258 Dihydroxyacetone (DHA) is a direct precursor of MG in Manuka honey [15]. The MGO
259 concentration in PHHs, determined by the N-acetyl-L-cysteine assay, was 0.26 ± 0.07 μ mol/mg
260 of proteins. The PHHs had higher MG concentration than bulk honey. MGO content is important

261 because it can serve as a suitable quality and cost parameter for Manuka honey. The H₂O₂ and
262 MG content is responsible for the antibacterial activity of honey [28] and PHHs maintain
263 antibacterial activity similar to that of bulk honey.

264 ***Microbiological analysis***

265 Manuka membranes did not show bacterial contamination after sterilization by gamma-
266 irradiation. Table 1 outlines the antibacterial activity based on the clear zone that was produced.

267 ***In vitro cytotoxicity assay***

268 Results concerning the effects induced by different concentrations of dissolved honey membrane
269 on viability of L929 cells are represented in Figure 1.

270 ***In vivo biocompatibility study***

271 Three rats from the treated group died of ascites in the first 24 hours. The gross evaluation in 36
272 rats showed no wound site infection or presence of adhesions. On performing histological
273 analysis 24 and 72 hours' post-surgery, the tissue near the implant was found to be characterized
274 by the presence of fibroblasts with some cellular response, including lymphocytes, macrophages,
275 and neovascularisation. No reaction was observed in distant organs. Thus, the PHHs did not
276 induce a foreign body reaction. The differences in the blood levels of the IL-1 β , IL-6, TNF- α and
277 PG(E2) at the 0, 6, 24, and 72 hours' time points were not statistically significant. The results are
278 summarized in Table 2.

279 **Discussion**

280 The new membranes may be used as wound dressings as they have a good WVTR and fluid
281 uptake and show no cytotoxicity to fibroblasts; they also have good swelling capability, which is
282 an important factor for reducing the risk of wound dehydration.

283

284

285 The results obtained by the cytotoxicity assay after 24 hours from the seeding, in presence of
286 decreasing concentrations of dissolved honey membranes, have shown a statistically significant
287 decrease ($p < 0.05$) of the cells treated with the highest concentration (0.1 g/ml) compared to the
288 control ones was observed. At 48 hours a trend in cell proliferation was found: highest
289 concentrations seemed to induce a inhibition in cell growth while decreasing the concentration,
290 the cell proliferation seemed to increase, even if it was not possible to highlight significant
291 differences. Also at this time point it was possible to appreciate a statistically significant
292 decreasing ($p < 0.05$) of the cells treated with the highest concentration (0.1 g/ml) compared to the
293 control.

294 After 72 hours of incubation, the highest concentrations (from 1:2 to 1:64) caused an inhibition in
295 cell growth while the lowest (1:256 and 1:512) induces a statistically significant increase in cell
296 growth compared to the control. During the *in vivo* experiments, tree rats died: in authors'
297 opinion, this was because of the excessively large sheet of membrane implanted intraperitoneally
298 because, initially, a dimension of 2×2 cm was chosen. Reducing the dimension of the implanted
299 PHHs to 1×1 cm did not cause any intraperitoneal accumulation of fluid, as determined from
300 macroscopic examination after euthanasia of the remaining rats. The tissue response to
301 intraperitoneal and subcutaneous implants showed a similar macroscopic and histological pattern.
302 In the light of PHHs antibacterial activity [12] and since administration of systemic antibiotics
303 does not always lead to good outcomes in terms of: wound healing, matrix penetration of the EPS
304 biofilm and antibiotic resistance, in this study we propose the use of Manuka honey to prepare
305 PHH for wound dressings. Interestingly, our membranes demonstrate a good antibacterial activity
306 toward clinically relevant pathogenic microorganisms such as *S. aureus* and *E. coli*.

307 Honey membranes possess a wide variety of properties that can make them suitable (as for other
308 natural materials such as chitosan hydrogels) [2, 24, 29], for very different uses that we can

309 hypothesise ranging from wound healing to adhesion prevention to drug delivery. The presence
310 of natural active components, conformability, and complete resorbability are the main
311 characteristics of this new biocompatible biomaterial that respects the pathophysiology of tissue,
312 is well tolerated by the body, possibly improves healing, and may be used for the prevention of
313 surgical complications. Furthermore, the production of these devices is extremely simple and
314 inexpensive.

315 **Acknowledgments**

316 The authors gratefully acknowledge the financial support from grant PRIN 2012.

317 **References**

- 318 1. Dave RN, Joshi HM, Venugopalan VP. Biomedical evaluation of a novel nitrogen oxides
319 releasing wound dressing. *J Mat Sci: Mat Med* 2012; 23: 3097–3106.
- 320 2. Shahzad S, Yar M, Siddiqi SA, Mahmood N, Rauf A, Qureshi ZA, et al. Chitosan-based
321 electrospun nanofibrous mats, hydrogels and cast films: novel anti-bacterial wound
322 dressing matrices. *J Mater Sci Mater Med* 2015; 26: 136-148.
- 323 3. Zhou G, Ruhan A, Ge H, Wang L, Liu M, Wang B, et al. Research on a novel poly (vinyl
324 alcohol)/lysine/vanillin wound dressing: Biocompatibility, bioactivity and antimicrobial
325 activity. *Burns* 2014; 40: 1668-1678.
- 326 4. Archana D, Singh BK, Dutta J, Dutta PK. Chitosan-PVP-nano silver oxide wound
327 dressing: In vitro and in vivo evaluation. *Int J Biol Macromol* 2015; 73, 49–57.
- 328 5. Das A, Kumar A, Patil NB, Viswanathan C, Ghosh D. Preparation and characterization
329 of silver nanoparticle loaded amorphous hydrogel of carboxymethylcellulose for infected
330 wounds. *Carbohydr Polym* 2015; 130: 254-261.
- 331 6. Godlee F. Antimicrobial resistance – an unfolding catastrophe. *Br Med J* 2013; 346:
332 f1663.

- 333 7. Harkins A, Duri S, Kloth LC, Tran CD. Chitosan-cellulose composite for wound dressing
334 material. Part 2. Antimicrobial activity, blood absorption ability, and biocompatibility. J
335 Biomed Mat Res Part B: Appl Biomat 2014; 102: 1199-1206.
- 336 8. Cooke J, Dryden M, Patton T, Brennan J, Barrett J. The antimicrobial activity of
337 prototype modified honeys that generate reactive oxygen species (ROS) hydrogen
338 peroxide. BMC Res Not 2015; 8: 1-5.
- 339 9. Sarhan WA, Azzary ME (2015) High concentration honey chitosan electrospun
340 nanofibers: Biocompatibility and antibacterial effects. Carbohydr Polym 2015; 122: 135-
341 143.
- 342 10. Emre A, Akin M, Isikgonul I, Yuksel O, Anadol AZ, Cifter C. Comparison of
343 intraperitoneal honey and sodium hyaluronate-carboxymethylcellulose (Septrafilm™) for
344 the prevention of postoperative intra-abdominal adhesions. Clin 2009; 64: 363-368.
- 345 11. Tan MK, Adli DSH, Tumiran MA, Abdulla MA, Yusoff KM. (2012) The efficacy of
346 gelam honey dressing towards excisional wound healing. Evid Based Complement
347 Alternat Med 2012; 2012: 805932.
- 348 12. Arne S, Kai S, Gertrud W, Gisela B, Udo B, Gudrun F. Wound care with antibacterial
349 honey (Medihoney) in pediatric hematology-oncology. J Supp Care Cancer 2006; 14: 91-
350 97.
- 351 13. Snow MJ, Manley-Harris M. On the nature of non-peroxide antibacterial activity in New
352 Zealand manuka honey. Food Chem 2004; 84: 145-147.
- 353 14. Çalamak S, Erdogdu C, Ozalp M, Ulubayram K. Silk fibroin based antibacterial
354 bionanotextiles as wound dressing materials. Mat Sci Eng C 2014; 43: 11–20.

- 355 15. Atrott J, Harberlau S, Henle T. Studies on the formation of methylglyoxal from
356 dihydroxyacetone in Manuka (*Leptospermum scoparium*) honey. *Carbohydrate Research*
357 2012;361:7–11.
- 358 16. Kwakman PHS, teVelde AA, de Boer L, Vandenbroucke-Grauls CM, Zaat SAJ. Two
359 major medicinal honeys have different mechanisms of bactericidal activity. *PLoS ONE*
360 2012; 6: e17709.
- 361 17. Shi L, Yang N, Zhang H, Chen L, Tao L, Wei Y, et al. A novel poly(γ -glutamic
362 acid)/silk-sericin hydrogel for wound dressing: Synthesis, characterization and biological
363 evaluation. *Mat Sci and Eng: C* 2015; 48: 533-540.
- 364 18. Walker JE. Method of preparing homogeneous honey pectin composition. Patented 1942;
365 September 8.
- 366 19. Carnwath R, Graham EM, Reynolds K, Pollock PJ. The antimicrobial activity of honey
367 against common equine wound bacterial isolates. *Vet J* 2014; 199: 110-114.
- 368 20. Long LH, Lan ANB, Hsuan FTY, Halliwell, B. Generation of hydrogen peroxide by
369 “antioxidant” beverages and the effect of milk addition. Is cocoa the best beverage? *Free*
370 *Radic Res* 1999; 31: 67–71.
- 371 21. Wild R, Ooi L, Srikanth V, Münch G. A quick, convenient and economical method for
372 the reliable determination of methylglyoxal in millimolar concentrations: the N-acetyl-L-
373 cysteine assay. *Anal Bioanal Chem* 2012; 403: 2577–2581.
- 374 22. Sherlock O, Dolan A, Athman R, Power A, Gethin G, Cowman S, et al. Comparison of
375 the antimicrobial activity of Ulmo honey from Chile and manuka honey against
376 methicillin-resistant *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas*
377 *aeruginosa*. *BMC Complement Altern Med* 2010; 47: 354–361.

- 378 23. Vercelli C, Barbero R, Re G. Transient receptor potential Vanilloid 1 in animal tissue: an
379 overview to highlight similarities and differences with human species. *Recept Clin Invest*
380 2015; 2: 1-9.
- 381 24. Azab AK, Doviner V, Orkin B, Kleinstern J, Srebnik M, Nissan A, et al.
382 Biocompatibility evaluation of crosslinked chitosan hydrogels after subcutaneous and
383 intraperitoneal implantation in the rat. *J Biomed Mat Res* 2007; 83: 414-422.
- 384 25. Majtan J, Bohova J, Prochazka E, Klaudiny J. Methylglyoxal may affect hydrogen
385 peroxide accumulation in manuka honey through the inhibition of glucose oxidase. *J*
386 *Med Food* 2014; 17: 290–293.
- 387 26. Brudzynski K, Abubaker K, St-Martin L, Castle A. Re-examining the role of hydrogen
388 peroxide in bacteriostatic and bactericidal activities of honey. *Front Microbiol* 2011; 2: 1-
389 9.
- 390 27. Bang LM, Buntting C, Molan P. The effect of dilution on the rate of hydrogen peroxide
391 production in honey and its implications for wound healing. *J Alter Compl Med* 2003; 9:
392 267–273.
- 393 28. Yusof N, Hazifa A, Zohdi RM, Bakar ZA. Development of honey hydrogel dressing for
394 enhanced wound healing. *Rad Physic Chem* 2007; 76: 1767–1770.
- 395 29. Zhang ZL, Xu SW, Zhou XL. Preventive effects of chitosan on peritoneal adhesion in
396 rats. *World J Gastroenterol* 2006; 12: 4572-4577.

397 **Table legend**

398 Table 1: Mean zones of inhibition (diameter [including that of the well], 6 mm)

399 Table 2: Results for blood levels of the IL-1 β , IL-6, TNF alpha and PG(E2)

400 **Figure legend**

401 Figure 1: MTT assay (N=8) to evaluate the modulation of L292 cells growth after the treatment
402 with decreasing concentrations of dissolved honey membrane in PBS at different experimental
403 time points (24, 48, and 72 hours).